Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

This study will evaluate the efficacy of TKI258 in patients with advanced urothelial cancer

Phase 2

Novartis Pharmaceuticals